TRPA1 and asthma: Another TRPA1 antagonist from Cubist Pharmaceuticals, CB-625 (structure not disclosed), was effective in reducing the late asthmatic response and antigen induced airway hyperresponsiveness upon oral dosing in sheep model of asthma [34].